Technical Analysis for DMPI - DelMar Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 0.48 -4.95% -0.03
DMPI closed up 2.06 percent on Thursday, March 21, 2019, on 2.05 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical DMPI trend table...

Date Alert Name Type % Chg
Mar 21 180 Bullish Setup Bullish Swing Setup -4.95%
Mar 21 Pocket Pivot Bullish Swing Setup -4.95%
Mar 21 Calm After Storm Range Contraction -4.95%
Mar 21 Upper Bollinger Band Walk Strength -4.95%
Mar 21 Wide Bands Range Expansion -4.95%
Mar 21 Above Upper BB Strength -4.95%
Mar 21 Overbought Stochastic Strength -4.95%
Mar 21 Up 3 Days in a Row Strength -4.95%
Mar 21 Up 4 Days in a Row Strength -4.95%
Mar 21 Up 5 Days in a Row Strength -4.95%

Older signals for DMPI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
Medicine Cancer Clinical Medicine Treatment Of Cancer Oncology Chemotherapy Drug Discovery Cancer Treatments Antineoplastic Drugs Drug Development Glioblastoma Leukemia Brain Tumor Lung Cancer Glioblastoma Multiforme Brain Cancer
Is DMPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.38
52 Week Low 0.281
Average Volume 180,207
200-Day Moving Average 0.5483
50-Day Moving Average 0.3754
20-Day Moving Average 0.3475
10-Day Moving Average 0.3788
Average True Range 0.0496
ADX 37.1
+DI 32.6078
-DI 17.904
Chandelier Exit (Long, 3 ATRs ) 0.4012
Chandelier Exit (Short, 3 ATRs ) 0.4298
Upper Bollinger Band 0.4709
Lower Bollinger Band 0.2241
Percent B (%b) 1.14
BandWidth 71.021583
MACD Line 0.0223
MACD Signal Line -0.0019
MACD Histogram 0.0241
Fundamentals Value
Market Cap 10.88 Million
Num Shares 21.6 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -0.68
Price-to-Sales 0.00
Price-to-Book 77.27
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.64
Resistance 3 (R3) 0.63 0.57 0.62
Resistance 2 (R2) 0.57 0.54 0.58 0.61
Resistance 1 (R1) 0.54 0.51 0.56 0.55 0.61
Pivot Point 0.48 0.48 0.49 0.49 0.48
Support 1 (S1) 0.45 0.44 0.46 0.46 0.40
Support 2 (S2) 0.39 0.42 0.39 0.40
Support 3 (S3) 0.35 0.39 0.39
Support 4 (S4) 0.37